Basic & Clinical Medicine ›› 2020, Vol. 40 ›› Issue (4): 547-551.

• Mini Reviews • Previous Articles     Next Articles

Research progress of nucleostemin signaling pathway in tumorigenesis and development

HE Zhen-hua1*, SHEN Fu-hui1,2, ZENG Fan-gang2, LIU Qian-lin2, YUAN Jing-min1   

  1. 1. Department of Neurosurgery;
    2. Department of Clinical Medicine, Lanzhou University Second Hospital, Lanzhou University Second Clinical College, Lanzhou 730000, China
  • Received:2019-07-11 Revised:2019-12-03 Online:2020-04-05 Published:2020-04-06
  • Contact: *changlang911@126.com

Abstract: Silencing nucleostemin (NS) can activate the p53 pathway and p53 inhibit proliferation of the tumor cell through the phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (PKB or AKT)/ mammalian target of rapamycin (mTOR) signal pathway. Low expression of NS also inhibits the PI3K/AKT/mTOR signal pathway through a non-p53 pathway. Inhibition of p53 activates the Wnt/β-catenin signal pathway. High expression of NS also activates the Wnt/β-catenin signal pathway. Over-expression of c-Myc increases NS expression and inhibits p53 expression,which may promote cell proliferation.

Key words: nucleostemin(NS), gene, protein, signal pathway

CLC Number: